Form 4: Vera Therapeutics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Marshall Fordyce, PRESIDENT AND CEO and a Director of Vera Therapeutics, Inc., sold 18,500 shares of common stock on September 15, 2026 for $37.00 per share.

Summary

  • Option exercise/conversion: acquired 18,500 Class A Common Stock at $2.90 ($53,591) on September 15, 2026; holds 253,744 after (Direct).
  • Open-market sale: disposed of 18,500 Class A Common Stock at $37.00 ($684,500) on September 15, 2026; holds 235,244 after (Direct).
  • Option exercise/conversion: disposed of 18,500 Stock Option (Right to Buy) on September 15, 2026; holds 488,801 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $684,500 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Marshall Fordyce — Director, Officer (PRESIDENT AND CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-15Option exercise/conversionClass A Common Stock18,500$3$53.6K253,744
2026-09-15Open-market saleClass A Common Stock18,500$37$684.5K235,244
2026-09-15Option exercise/conversionStock Option (Right to Buy)18,500——488,801

Key Dates

DateDescription
2026-09-15Option exercise/conversion (18,500 shares)
2026-09-15Open-market sale (18,500 shares)
2026-09-15Option exercise/conversion (18,500 shares)

Keywords

insider transaction, Form 4, VERA, Vera Therapeutics, Inc., bearish, Marshall Fordyce

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.